Cyclerion Therapeutics Inc
CYCN
查看详细走势图
1.380USD
-0.050-3.50%
收盘 12/24, 13:00（美东）报价延迟15分钟
5.10M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-3.50%
5天
-9.21%
1月
-7.38%
6月
-53.94%
今年开始到现在
-57.14%
1年
-58.05%
查看详细走势图
TradingKey Cyclerion Therapeutics Inc股票评分
单位: USD 更新时间: 2025-12-24操作建议
Cyclerion Therapeutics Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名214/404位。机构持股占比非常高，中期看，股价处于下降通道。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Cyclerion Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
0
位分析师
--
评级
0.000
目标均价
0.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Cyclerion Therapeutics Inc亮点
亮点风险
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
业绩高增长
公司营业收入稳步增长，连续3年增长573.40%
业绩增长期
公司处于发展阶段，最新年度总收入2.00M美元
估值合理
公司最新PE估值-1.96，处于3年历史合理位
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值23.49K
Cyclerion Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Cyclerion Therapeutics Inc简介
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
公司代码CYCN
公司Cyclerion Therapeutics Inc
CEOGraul (Regina M)
网址https://www.cyclerion.com/
常见问题
Cyclerion Therapeutics Inc(CYCN)的当前股价是多少？
Cyclerion Therapeutics Inc(CYCN)的当前股价是 1.380。
Cyclerion Therapeutics Inc的股票代码是什么？
Cyclerion Therapeutics Inc的股票代码是CYCN。
Cyclerion Therapeutics Inc股票的52周最高点是多少？
Cyclerion Therapeutics Inc股票的52周最高点是6.250。
Cyclerion Therapeutics Inc股票的52周最低点是多少？
Cyclerion Therapeutics Inc股票的52周最低点是1.280。
Cyclerion Therapeutics Inc的市值是多少？
Cyclerion Therapeutics Inc的市值是5.10M。
Cyclerion Therapeutics Inc的净利润是多少？
Cyclerion Therapeutics Inc的净利润为-3.06M。
现在Cyclerion Therapeutics Inc(CYCN)的股票是买入、持有还是卖出？
根据分析师评级，Cyclerion Therapeutics Inc(CYCN)的总体评级为--，目标价格为--。
Cyclerion Therapeutics Inc(CYCN)股票的每股收益（EPS TTM）是多少
Cyclerion Therapeutics Inc(CYCN)股票的每股收益（EPS TTM）是-0.704。
相关品种
